Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Verona Pharma plc - American Depositary Shares (NQ:VRNA)

104.90 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Verona Pharma plc - American Depositary Shares

< Previous 1 2 3 4 5 Next >
Does This Move Make Merck Stock a Buy?
Via The Motley Fool
Topics Intellectual Property
Is the Market Bullish or Bearish on Verona Pharma?
Via Benzinga
Merck Just Announced a $10 Billion Deal That Will Help Diversify Its Business
Via The Motley Fool
Topics Intellectual Property
The trading volume of these stocks is deviating from the norm in today's session.
In today's session, these stocks are experiencing unusual volume. 
Via Chartmill
This Procter & Gamble Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Via Benzinga
Is Verona Pharma Gaining or Losing Market Support?
Via Benzinga
Earnings Scheduled For April 29, 2025
Via Benzinga
Earnings Scheduled For February 27, 2025
Via Benzinga
Nvidia's $4 Trillion Milestone Lifts Wall Street: What's Moving Markets Wednesday?
Wall Street rose on Wednesday as investors shrugged off fresh trade uncertainty after the White House delayed the start of new tariffs to Aug. 1, raising hopes for new rounds of negotiations. 
Via Benzinga
Topics World Trade
Verona Pharma, Rhythm Pharmaceuticals, AES And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Which stocks are gapping on Wednesday?
The session on Wednesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
Via Chartmill
Merck Strikes $10-Billion Deal For Verona, Secures First-In-Class COPD Drug
Merck is acquiring Verona Pharma for $10 billion, gaining COPD drug Ohtuvayre as part of its strategy to offset Keytruda's looming patent loss. 
Via Benzinga
Topics Intellectual Property
Merck Plots $10 Billion Takeover Of COPD Drugmaker Verona Pharma
The takeover target just launched its first drug last summer. Shares have mostly trended higher since. 
Via Investor's Business Daily
Topics Government
These stocks are moving in today's pre-market session
As the US market prepares to open on Wednesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Merck To Acquire Verona For $10B In Bid To Expand Cardio-Pulmonary Pipeline
Merck will acquire Verona for $107 per American Depository Share (ADS), each of which represents eight Verona Pharma ordinary shares, for a total transaction value of approximately $10 billion. 
Via Stocktwits
Topics Government
Why AES Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
Shares of The AES Corporation (NYSE:AES) rose sharply in pre-market trading following reports the company has received takeover interest. 
Via Benzinga
This Rollins Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Via Benzinga
4 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Oracle To Rally More Than 20%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Investing $15,000 Into Each of These 3 Stocks 5 Years Ago Would Have Created a Portfolio Worth $1 Million Today
Via The Motley Fool
Regeneron, Sanofi Stock Falls After Uneven Smoker's Lung Drug Data
Regeneron and Sanofi's COPD drug itepekimab cut exacerbations by 27% in one Phase 3 trial, while the second trial did not meet its main goal. 
Via Benzinga
Jim Cramer Says This Quantum Computing Stock Is 'So High' And 'Too Speculative'
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Why Verona Pharma, A Triple-Digit Gainer In 2024, Surged Another 22% This Week
The company is working to launch its COPD treatment more broadly. The drug is a non-steroidal nebulizer. 
Via Investor's Business Daily
Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent
The FDA signed off on Regeneron and Sanofi's Dupixent for patients with uncontrolled COPD. 
Via Investor's Business Daily
Petco, AppLovin, Dave & Buster's And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
GSK's Asthma Drug Meets Main Goal In Phase 3 Study In Patients With Smoker's Lungs, Prepares Competition With Amgen/AstraZeneca's Drug
GSK's Phase 3 MATINEE trial of Nucala in COPD met the primary endpoint, reducing exacerbations significantly over 104 weeks. 
Via Benzinga
Top 3 Health Care Stocks That May Crash In August
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.